Robot-assisted surgery cuts costs, recovery time

May 21, 2019

Published by Harvest ETFs

Medical device companies are expanding their research and development initiatives to bring more robot-assisted surgery to operating rooms.

One area that is growing is orthopedic surgery, where global medical devices giants including Stryker Corp. and Medtronic Corp. are competing to introduce machines that cost more than $1 million each.

These robotic aids are designed to help surgeons be more precise and perform surgery that is less invasive. This is leading to faster patient recovery and satisfaction, a reduction in post-operative pain, a reduction in length of hospital stay and fewer readmissions due to complications.

Stryker Corp. has sold more than 650 of its Mako robots globally, with almost 77,000 knee and hip replacement procedures performed in 2018. Double-digit growth in installations is expected in 2019, according to a recent industry estimates. Stryker acquired Mako for US. $1.7 billion 5 years ago.

In the case of knee replacement, the Mako system takes a CT scan of the knee and converts it into a three-dimensional model of the knee joint. The surgeon uses the scan to preoperatively plan the surgery. Once the plan is approved, it is loaded into the robot. In the operating room, the computer model is compared to the patient’s actual motion in bending and straightening out the knee or hip. The patient movements are replicated on the robot’s computer screen.

After the adjustments, the final plan is locked in and the arm assists the surgeon performing the cuts.

Medtronic is moving forward with its own surgical robots. In December, 2018 it paid US $1.7 billion for Mazor Robotics, an Israeli specialist in robot-assisted spinal surgery. Robotic spine surgery is a safer, less invasive and precise alternative to the traditional open spine surgery.

Stryker  and Medtronic are two components of the Harvest Healthcare Leaders Income ETF (HHL:TSX, HHL.U:TSX).  Both companies offer a broad range of medical devices and equipment and are benefiting from advances in robotics and artificial intelligence.

As of April 30, 2019, HHL held 20 of the largest global healthcare companies with an average market capitalization of $158 billion (CAD). The holdings have an average dividend yield of 2.19% and a 5-year return on equity of 19.97%.

The management fee is 0.85% and the fund is RRSP, RRIF, RESP and TFSA eligible with a distribution paid monthly.

For more on Harvest Portfolio Group click here.

The views and/or opinions expressed in the blog are of a general nature and are for informational purposes only. Blog contents should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies. Investors should consult their investment advisor before making any investment decision. 


You may also like…


For Information Purposes Only. Commissions, management fees and expenses all may be associated with investing in HARVEST Exchange Traded Funds (managed by Harvest Portfolios Group Inc.) Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. This communication should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies. Tax, investment and all other decisions should be made with guidance from a qualified professional.

Certain statements in the Harvest Blog are forward looking Forward-looking statements (“FLS”) are statements that are predictive in nature, depend upon or refer to future events or conditions, or that include words such as “may,” “will,” “should,” “could,” “expect,” “anticipate,” “intend,” “plan,” “believe,” or  “estimate,” or other similar expressions. Statements that look forward in time or include anything other than historical information are subject to risks and uncertainties, and actual results, actions or events could differ materially from those set forth in the FLS.

FLS are not guarantees of future performance and are by their nature based on numerous assumptions, which include, amongst other things, that (i) the Fund can attract and maintain investors and have sufficient capital under management to effect their investment strategies, (ii) the investment strategies will produce the results intended by the portfolio managers, and (iii) the markets will react and perform in a manner consistent with the investment strategies. Although the FLS contained herein are based upon what the portfolio manager believe to be reasonable assumptions, the portfolio manager cannot assure that actual results will be consistent with these FLS.

Unless required by applicable law, Harvest Portfolios Group Inc. does not undertake, and specifically disclaim, any intention or obligation to update or revise any FLS, whether as a result of new information, future events or otherwise.

Sign up to receive our monthly updates